GLPwatch
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
NCT04741074 · Terminated
Last updated 2026-05-28This clinical trial is testing whether a medication called semaglutide, given as an injection under the skin, can help people with obesity, type 2 diabetes, and chronic kidney disease become eligible for a kidney transplant.
What this study is testing ClinicalTrials.gov NCT04741074 ↗
Description as written by the study sponsor.
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Treatments tested
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution also known as semaglutide Drug
Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
- Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution also known as placebo Drug
Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
| Main thing measured | Kidney Transplant Eligibility |
|---|---|
| Sponsor | Geisinger Clinic |
| Conditions studied | CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04741074 ↗